Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Ameet I. Thaker; Anisa Shaker; M. Suprada Rao; Matthew A. Ciorba

doi:10.3791/4100

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

JoVE Journal
Medicine
Author Produced

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Medicine

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Full Text

48,196 Views

12:37 min

September 11, 2012

DOI: 10.3791/4100-v

Ameet I. Thaker¹, Anisa Shaker¹, M. Suprada Rao¹, Matthew A. Ciorba¹

¹Division of Gastroenterology,Washington University School of Medicine

We demonstrate a protocol in which administration of the genotoxic agent azoxymethane (AOM) followed by three cycles of the pro-inflammatory agent dextran sulfate sodium (DSS) rapidly and consistently generates colon tumors in mice with morphologic and molecular similarities to those seen in human colitis-associated cancer.

On day zero, Myer injected with azoxymethane or a OM the following week. Their drinking water is replaced with a solution containing dextran sulfate sodium or DSS. At week three, mice are given water for the following two weeks.

This DSS water cycle is repeated two additional times. After the second DSS cycle. Mice can be assessed for tumors by mirroring endoscopy.

View the full transcript and gain access to thousands of scientific videos

Explore More Videos

Colitis-associated Cancer Azoxymethane Dextran Sulfate Sodium Inflammatory Bowel Disease Crohn's Disease Ulcerative Colitis Colorectal Cancer Adenocarcinomas Animal Models Of CAC DSS-induced Chronic Inflammatory State Tumorigenesis Pathways Genetic Mutations Genotoxic Agents